Combination strategies incorporating PARP inhibitors, antiangiogenic agents, and immune checkpoint blockade were also reviewed.<h4>Results</h4>Checkpoint inhibitors have achieved meaningful clinical benefits in patients with advanced or recurrent endometrial and cervical cancers, particularly in those with mismatch repair deficiency or PD-L1 expression. Here, CD274 is linked to cervical carcinoma.